$523.53
5.931.15%
At close: -
$524.99
1.460.28%
After Hours: 7:37 PM EDT
Comments
Loading...
Latest Regeneron Pharmaceuticals Stock News | NASDAQ:REGN | Benzinga
Get the latest news on Regeneron Pharmaceuticals stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Regeneron Pharmaceuticals performance
Categories: All
Tuesday, June 10, 2025
Monday, June 09, 2025
Thursday, June 05, 2025
Wednesday, June 04, 2025
Tuesday, June 03, 2025
Monday, June 02, 2025
- Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target
- Citigroup Maintains Buy on Regeneron Pharmace...
- Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response
- BMO Capital Maintains Outperform on Regeneron...
- Morgan Stanley Maintains Overweight on Regene...
- Regeneron Pharmaceutical Announced A Strategi...
- Reported Saturday, Regeneron's Libtayo Demons...
Sunday, June 01, 2025
Saturday, May 31, 2025
Friday, May 30, 2025
- Forecasting The Future: 21 Analyst Projections For Regeneron Pharmaceuticals
- Wells Fargo Downgrades Regeneron Pharmaceutic...
- Regeneron Pharmaceuticals Unusual Options Activity For May 30
- Looking Into Regeneron Pharmaceuticals's Recent Short Interest
- Elastic, Gap, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
- Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
- Market-Moving News for May 30th
- Regeneron shares are trading lower after the ...
- Sanofi And Regeneron To Consult Regulators Af...
Wednesday, May 28, 2025
Tuesday, May 27, 2025
Thursday, May 22, 2025
Monday, May 19, 2025
Friday, May 16, 2025
Thursday, May 15, 2025
Wednesday, May 14, 2025
- Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
- Beyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock
- Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?
- This PVH Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
- Citigroup Upgrades Regeneron Pharmaceuticals ...
